טוען...
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
BACKGROUND: The real-world data for the effectiveness and safety of sofosbuvir/ledipasvir (SOF/LDV) with or without ribavirin (RBV) in patients with hepatitis C virus genotype 1 (HCV-1) infection remain limited in Taiwan. METHODS: A total of 273 chronic HCV-1 patients receiving 8, 12, or 24 weeks of...
שמור ב:
| הוצא לאור ב: | PLoS One |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Public Library of Science
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6303025/ https://ncbi.nlm.nih.gov/pubmed/30576344 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0209299 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|